Public Advisory - Unauthorized treatments provided by individual posing as a practitioner at MedSkin Laser Center in Sherwood Park, Alberta, may pose health risks
OTTAWA, ON, Aug. 2, 2024 /CNW/ -
Summary
Product: Unauthorized Platelet Rich Plasma (PRP) treatments, Botox and medical devices
Issue: Health products ? Product safety; Unauthorized product
What to do: Do not receive unauthorized treatments (see list below) from MedSkin Laser Center. Consult a licensed health care professional if you have received a treatment from MedSkin Laser Center and have health concerns.
Unauthorized Platelet Rich Fibrin (PRF) for scalp, eyes, acne, face, neck, jaw line, hands and decolletage
Botox (DIN 01981501)
Unauthorized Microneedles and Microneedle Tips
Unauthorized Plasma Pen
Issue
Health Canada is warning the public about various unauthorized treatments that were being administered at MedSkin Laser Center in Sherwood Park, Alberta, where the owner and operator of the clinic was posing as a practitioner without the necessary qualifications.
This includes the unauthorized Platelet Rich Plasma (PRP) treatments listed above for hair restoration, breast enhancements, rejuvenating skin and muscles, wound healing and face lifts. Unauthorized PRPs could lead to serious health risks, including the potential transmission of infectious diseases, contaminants, and toxic effects.
Health Canada also seized prescription Botox from the MedSkin Laser Centre, because prescription drugs should only be given by a health care professional with the appropriate qualifications and experience. Using prescription drugs without a proper prescription and the advice of a qualified practitioner could lead to serious harm such as side effects, allergic reactions, severe complications and other medical issues.
Finally, the Department also seized unauthorized medical devices including microneedles, microneedle tips, and a plasma pen.
What you should do
Do not receive unauthorized treatments from MedSkin Laser Center. Consult a licensed practitioner if you have received a treatment from MedSkin Laser Center and have health concerns.
Check the status of those presenting themselves as practitioners with the College of Physicians and Surgeons in your province or territory.
Report concerns regarding the illegal practice of medicine to the College of Physicians and Surgeons in your province or territory.
Read product labels to verify that health products have been authorized for sale by Health Canada. Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM). You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database. For medical devices, although the Medical Device Licence (MDL) number is not required to appear on the product label, authorized medical devices can be found by search of Health Canada's Medical Devices Active Licence Listing (MDALL).
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some...
After a summer of excessive heat, massive flooding, raging wildfires and the earliest Category 5 hurricane ever recorded, communities and families are feeling the effects of the climate crisis ? and relying on the American Red Cross for support ? now...
Olink Proteomics, part of Thermo Fisher Scientific, a leading provider of advances proteomics solutions, is exited to announce its upcoming virtual conference, Olink...
ADESOS Phase 2b results with orismilast in atopic dermatitis (AD) selected as late-breaking oral presentationAdditionally, two posters on data from the pioneering use of tape stripping for biomarker analysis in the ADESOS study and additional ADESOS...
CD (Suzhou) Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human trial.
CD-001, the company's leading clinical candidate, is...